Biogen Paper, page-22

It's always a good idea to consider what evidence is apparent today, and it's an especially good idea to put aside abstracts of old events (no matter the date finally published) if there is more relevant information in real time.

Argumentativeness isn't pleasant and hopefully can be put to rest. Two posters requested discussion of what they think is a competing drug producer (lol) when they discovered what they thought was a "gotcha" moment for whatever reason.

They were wrong. As cited above, professionals at the FDA have found Biogen's aducanumab worthy of commencing two very large multi-national late-stage Phase III trials. Professionals in Europe have approved admission for aducanumab to EMA's PRIME system which has special advisory and time advantages.

In contrast, after failure of the Imagine Phase II AD, Prana is nowhere near starting another AD trial at any stage and no matter what might be said at AAIC. As we know, Prana has never had any drug reach Phase III late stage status. PBT2 is not participating in any European trials and of course Prana has not made any public announcement of requesting trial admission to the EMA.

At any rate, this topic and thread hasn't been very helpful to Prana's cause imho. There are many other drug developers than Prana Biotech and Biogen under the sun. It isn't very productive to try to find pros and cons of those two and ignore everything else that is going on in the biotech world.